SPOTLIGHT: Vicuron files NDA

Vicuron Pharmaceuticals has filed an NDA for anidulafungin for the treatment of invasive candidiasis/candidemia, the most common hospital-acquired fungal infection. The NDA was filed as the biotech had planned. Story